Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B13 | Q7Z5P4 | 4/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609491 | 0.90 | MEN1 (0.33) | MEN1KMT2AKDM4EHSD17B13MAPT | |
| Hydrochloric Acid SCHEMBL4935864 | 0.89 | MEN1 (0.33) | MEN1KMT2AKDM4EHSD17B13MAPT | |
| SCHEMBL7906718 | 0.89 | TLR7 (0.35) | HSD17B13SRCGRIA1GRIA2GRIA3 | |
| SCHEMBL7904050 | 0.87 | GRIA1 (0.33) | MEN1KMT2AKDM4EHSD17B13SRC | |
| SCHEMBL7904656 | 0.87 | LMNA (0.34) | MEN1KMT2AKDM4EHSD17B13MAPT | |
| SCHEMBL7903482 | 0.85 | HSD17B13 (0.37) | HSD17B13 | |
| SCHEMBL7904142 | 0.85 | CDK1 (0.34) | MEN1KMT2AKDM4EHSD17B13MAPT | |
| SCHEMBL7896785 | 0.82 | ALDH1A1 (0.36) | KMT2AKDM4EHSD17B13SRCGRIA1 | |
| SCHEMBL7902745 | 0.81 | KDM4E (0.37) | MEN1KMT2AKDM4EHSD17B13SRC | |
| SCHEMBL7903311 | 0.81 | CDK4 (0.33) | MEN1KMT2AHSD17B13MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379510-B1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2016-10-26 | — | — | EP | disclosed |
| US-20150359796-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-12-17 | — | — | US | disclosed |
| US-20150359796-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-12-17 | — | — | US | disclosed |
| US-9145375-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-09-29 | — | — | US | disclosed |
| US-9145375-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-09-29 | — | — | US | disclosed |
| US-20150025072-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| US-20150025072-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| US-8889695-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-11-18 | — | — | US | disclosed |
| US-8889695-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-11-18 | — | — | US | disclosed |
| EP-1737831-B1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2013-05-22 | — | — | EP | disclosed |
| US-20120040980-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-02-16 | — | — | US | disclosed |
| US-20120040980-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-02-16 | — | — | US | disclosed |
| US-8084459-B2 | 8-hydroxy-3H-quinazolin-4-(thi)one derivatives; ability to enter CNS, sequester transition metals Cu, Zn and Fe from various amiloid beta entities, reducing their toxicity; neurodegenerative disorders; Alzheimer's, Parkinson's, Cruetzfeldt-Jacob diseases, amyotrophic lateral sclerosis, cataract | PRANA BIOTECHNOLOGY LTD (AU) | 2011-12-27 | — | — | US | disclosed |
| US-8084459-B2 | 8-hydroxy-3H-quinazolin-4-(thi)one derivatives; ability to enter CNS, sequester transition metals Cu, Zn and Fe from various amiloid beta entities, reducing their toxicity; neurodegenerative disorders; Alzheimer's, Parkinson's, Cruetzfeldt-Jacob diseases, amyotrophic lateral sclerosis, cataract | PRANA BIOTECHNOLOGY LTD (AU) | 2011-12-27 | — | — | US | disclosed |
| WO-2010071944-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-07-01 | — | — | WO | disclosed |
| US-20080119470-A1 | Neurologically-Active Compounds | XOMA TECHNOLOGY LTD. | 2008-05-22 | — | — | US | disclosed |
| US-20080119470-A1 | Neurologically-Active Compounds | XOMA TECHNOLOGY LTD. | 2008-05-22 | — | — | US | disclosed |
| WO-2005095360-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150359796-A1 | QUINAZOLINONE COMPOUNDS | PARK7, SNCA, NDUFV2 | MEN1 3621/4885KMT2A 4294/4885KDM4E 3990/4885 |
| US-20080119470-A1 | Neurologically-Active Compounds | ACHE, PSEN1, PSEN2 | MEN1 1779/4885KMT2A 1955/4885KDM4E 1854/4885 |
| US-20150025072-A1 | QUINAZOLINONE COMPOUNDS | PARK7, SNCA, NQO2 | MEN1 3555/4885KMT2A 4045/4885KDM4E 3927/4885 |
| US-20120040980-A1 | QUINAZOLINONE COMPOUNDS | PARK7, SNCA, NQO2 | MEN1 3555/4885KMT2A 4045/4885KDM4E 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.